Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: Possible relevance to infantile haemangioma pathogenesis

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 308-315

  Herbert, A ^a   Ng, H ^a,b   Jessup, W ^c   Kockx, M ^c   Cartland, S ^c   Thomas, S R ^c   Hogg, Philip J ^a   Wargon, O ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CYTOKINE; GLUCOSE TRANSPORTER 1; INDOLEAMINE 2,3 DIOXYGENASE;

ARTICLE; CAPILLARY HEMANGIOMA; CELL HYPOXIA; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MARKER; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYPOXEMIA; IMMUNOCOMPETENT CELL; ISCHEMIA; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY;

CELL HYPOXIA; CELLS, CULTURED; ENDOTHELIAL CELLS; GLUCOSE TRANSPORTER TYPE 1; HEMANGIOMA; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551477978     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10086.x     Document Type: Article

References (48)

1. Claesson-Welsh L,. Healing hemangiomas. Nat Med 2008; 14: 1147-8.
2. Mulliken JB, Fishman SJ, Burrows PE,. Vascular anomalies. Curr Probl Surg 2000; 37: 517-84.
3. Amir J, Metzker A, Krikler R, et al. Strawberry hemangioma in preterm infants. Pediatr Dermatol 1986; 3: 331-2.
4. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150: 291-4.
5. Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14: 1236-46.
6. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103: 1373-5.
7. Kleinman ME, Tepper OM, Capla JM, et al. Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. Lymphat Res Biol 2003; 1: 301-7.
8. Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118: 2592-9.
9. Nguyen VA, Furhapter C, Romani N, et al. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol 2004; 35: 739-44.
10. Ritter MR, Reinisch J, Friedlander SF, et al. Myeloid cells in infantile hemangioma. Am J Pathol 2006; 168: 621-8.
11. Rehman J, Li J, Orschell CM, et al. Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-9.
12. Bouchentouf M, Paradis P, Forner KA, et al. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant 2010; 19: 369-86.
13. Glod J, Kobiler D, Noel M, et al. Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood 2006; 107: 940-6.
14. Elsheikh E, Uzunel M, He Z, et al. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood 2005; 106: 2347-55.
15. Fujiyama S, Amano K, Uehira K, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 2003; 93: 980-9.
16. Zhao Y, Glesne D, Huberman E,. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 2003; 100: 2426-31.
17. Fernandez Pujol B, Lucibello FC, Gehling UM, et al. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 2000; 65: 287-300.
18. Jia J, Huang X, Zhang WF, et al. Human monocyte-derived hemangioma-like endothelial cells: evidence from an in vitro study. Cardiovasc Pathol 2008; 17: 212-18.
19. Jia J, Zhang WF, Zhao YF,. Monocytes: a possible source of hemangioma endothelial cells. Med Hypotheses 2007; 68: 98-100.
20. Kleinman ME, Blei F, Gurtner GC,. Circulating endothelial progenitor cells and vascular anomalies. Lymphat Res Biol 2005; 3: 234-9.
21. Al Buainian H, Verhaeghe E, Dierckxsens L, et al. Early treatment of hemangiomas with lasers. A review. Dermatology 2003; 206: 370-3.
22. Hamlat A, Adn M, Pasqualini E, et al. Pathophysiology of capillary haemangioma growth after birth. Med Hypotheses 2005; 64: 1093-6.
23. Lopez Gutierrez JC, Avila LF, Sosa G, et al. Placental anomalies in children with infantile hemangioma. Pediatr Dermatol 2007; 24: 353-5.
24. Ogino S, Redline RW,. Villous capillary lesions of the placenta: distinctions between chorangioma, chorangiomatosis, and chorangiosis. Hum Pathol 2000; 31: 945-54.
25. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007; 27: 2664-70.
26. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-64.
27. Wouters BG, van den Beucken T, Magagnin MG, et al. Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev Biol 2005; 16: 487-501.
28. Semenza GL,. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167-71.
29. Rathmell WK, Acs G, Simon MC, Vaughn DJ,. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Res 2004; 24: 167-9.
30. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22.
31. Enjolras O, Picard A, Soupre V,. [Congenital haemangiomas and other rare infantile vascular tumours]. Ann Chir Plast Esthet 2006; 51: 339-46.
32. Ritter MR, Moreno SK, Dorrell MI, et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol 2003; 1: 291-9.
33. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
34. Friedlander SF, Ritter MR, Friedlander M,. Recent progress in our understanding of the pathogenesis of infantile hemangiomas. Lymphat Res Biol 2005; 3: 219-25.
35. Kuwana M, Okazaki Y, Kodama H, et al. Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 2006; 24: 2733-43.
36. Thomas SR, Salahifar H, Mashima R, et al. Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 2001; 166: 6332-40.
37. Thomas SR, Stocker R,. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999; 4: 199-220.
38. Mathupala SP, Ko YH, Pedersen PL,. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 2010; 1797: 1225-30.
39. Medina RA, Owen GI,. Glucose transporters: expression, regulation and cancer. Biol Res 2002; 35: 9-26.
40. Rempel A, Bannasch P, Mayer D,. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1994; 1219: 660-8.
41. Pedersen PL, Mathupala S, Rempel A, et al. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002; 1555: 14-20.
42. Goel A, Mathupala SP, Pedersen PL,. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003; 278: 15333-40.
43. Mathupala SP, Rempel A, Pedersen PL,. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276: 43407-12.
44. Lewis C, Murdoch C,. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005; 167: 627-35.
45. Murdoch C, Giannoudis A, Lewis CE,. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224-34.
46. Kawaguchi R, Shimokawa T, Umehara N, et al. Priming of peripheral monocytes with prolactin (PRL) sensitizes IFN-gamma-mediated indoleamine 2,3-dioxygenase (IDO) expression without affecting IFN-gamma signaling. J Reprod Immunol 2008; 77: 117-25.
47. Mellor AL, Munn DH,. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
48. Grohmann U, Fallarino F, Puccetti P,. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24: 242-8.